130 completed, 18 unknown, 11 terminated, 5 withdrawn. 54 Phase 1, 48 Phase 3, 39 Phase 4, 9 Not applicable, 9 Phase 2.
Follow Linagliptin: new trials by email Literature Review of Linagliptin trials Research Report on Linagliptin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study on Improving Blood Glucose Homeostasis With Dorzagliatin Tablets in the Treatment of Type 2 Diabetes Mellitus Patients With Moderate to Severe Chronic Renal Insufficiency Dorzagliatin, Linagliptin - Type 2 Diabetes Mellitus (T2DM), Chronic Renal Insufficiency | Not applicable | Withdrawn | Sun Yat-sen University | 2026-12-01 | 2026-10-16 | |
| Metformin, Empagliflozin With Sitagliptin vs Linagliptin in Type 2 Diabetes Metformin+ Empagliflozin + Sitagliptin, Metformin + Empagliflozin + Linagliptin - Type 2 Diabetes Mellitus | Phase 4 | Enrolling by invitation | Bahria University | 110 | 2026-01-01 | 2026-03-05 |
| Glycemic Variability of Combination Therapies in T2DM Empagliflozin/Metformin, Anagliptin, Metformin - Type 2 Diabetes Mellitus (T2DM) | Phase 4 | Recruiting | JW Pharmaceutical | 178 | 2025-10-29 | 2026-03-02 |
| Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. Metformin, Dulaglutide, Semaglutide 1.0 mg - Diabetes Mellitus Type 2 | Phase 4 | Completed | Fundación para la Investigación del Hospital Clínico de Valencia | 92 | 2025-05-26 | 2026-09-04 |
| Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus MADALENA ASSOCIATION, METFORMIN, EMPAGLIFLOZIN + LINAGLIPTIN - Type 2 Diabetes Mellitus | Phase 3 | Recruiting | EMS | 270 | 2024-11-18 | 2025-12-08 |
| The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers Linagliptin 5 mg Oral Tablet, Trajenta 5 MG Oral Tablet - Healthy Volunteer | Phase 1 | Unknown | International Bio service | 48 | 2024-04-24 | 2024-02-07 |
| Efficacy and Safety of LID104 in the Treatment of Type II Diabetes Mellitus LID104, Dapagliflozin, Linagliptin - Type 2 Diabetes Mellitus | Phase 3 | Not yet recruiting | EMS | 597 | 2024-02-01 | 2023-06-02 |
| Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus Empagliflozin 25 MG, Linagliptin 5 mg Oral Tablet - Diabetes Mellitus, Kidney Transplant; Complications | Not applicable | Unknown | Medanta, The Medicity, India | 200 | 2023-11-10 | 2023-10-24 |
| Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus Empagliflozin 25 MG, Linagliptin - Kidney Transplant; Complications, Diabetes Mellitus | Not applicable | Recruiting | Medanta, The Medicity, India | 200 | 2023-10-30 | 2024-12-05 |
| The Efficacy and Safety of Empagliflozin - Linagliptin and Empagliflozin- Metformin Therapy in Reduction of Body Weight in Type 2 Diabetic Patients . (Empagliflozin 10 mg+ Tab Linagliptin 5mg), Tab Empagliflozin 10 mg + Tab Metformin 500 mg - Diabete Mellitus | Phase 4 | Completed | Bahria University | 200 | 2022-12-01 | 2025-11-25 |
| LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes Liraglutide, Empagliflozin, Linagliptin - Type 2 Diabetes Mellitus, Mild Cognitive Impairment | Not applicable | Completed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 396 | 2022-10-08 | 2026-08-06 |
| Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes Insulin Degludec and Insulin Aspart - Liver Cirrhosis, Diabetes | Phase 3 | Unknown | Huashan Hospital | 184 | 2022-10-01 | 2022-12-07 |
| Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects Test Empagliflozin And Linagliptin Tablets, Reference Empagliflozin And Linagliptin tablets - Healthy | Phase 1 | Completed | The Affiliated Hospital of Qingdao University | 106 | 2022-07-01 | 2023-07-21 |
| Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus Empagliflozin/Linagliptin - Diabetes Mellitus, Type 2 | Completed | Boehringer Ingelheim | 1053 | 2022-03-22 | 2025-08-27 | |
| Cognitive Protective Effect of Newer Antidiabetic Drugs Dapagliflozin, Empagliflozin, Canagliflozin - Type 2 Diabetes | Unknown | Alexandria University | 100 | 2022-03-02 | 2022-07-26 | |
| Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome Empagliflozin 25 mg, Linagliptin 10 mg, Metformin 1500 mg - Polycystic Ovary Syndrome (PCOS) | Phase 4 | Unknown | Alexandria University | 75 | 2021-12-07 | 2022-01-21 |
| Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus. LIMA association, Tradjenta, Forxiga - Type2 Diabetes Mellitus | Phase 3 | Withdrawn | EMS | 2021-12-01 | 2022-07-27 | |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes | Active not recruiting | Brigham and Women's Hospital | 781430 | 2021-08-01 | 2026-08-13 | |
| Comparison of Type 2 Diabetes Pharmacotherapy Regimens SU, DPP4, SGLT2i - Type 2 Diabetes Mellitus, Cardiovascular Diseases | Completed | Kaiser Permanente | 241981 | 2021-07-01 | 2025-11-21 | |
| Effects of DPP4 Inhibition on COVID-19 Linagliptin, Insulin regimen - Coronavirus Infection, Type 2 Diabetes | Phase 4 | Withdrawn | University of Miami | 2021-06-30 | 2021-06-10 |
Showing 20 of 170. Sign in to see all of them.
Diabetes Mellitus, Type 2 (89) · Diabetes Mellitus (20) · Prediabetic State (6) · Insulin Resistance (5) · COVID-19 (3) · Hyperglycemia (3) · Hypertension (3) · Renal Insufficiency (3) · Albuminuria (2) · Coronavirus Infections (2) · Diabetic Nephropathies (2) · Renal Insufficiency, Chronic (2) · Schizophrenia (2) · Ventricular Dysfunction, Left (2) · Carcinoma, Non-Small-Cell Lung (1)
Boehringer Ingelheim (89) · Universidad de Guanajuato (5) · EMS (3) · Alexandria University (2) · Bahria University (2) · Boryung Pharmaceutical Co., Ltd (2) · Brigham and Women's Hospital (2) · Emory University (2) · Hoffmann-La Roche (2) · Medanta, The Medicity, India (2) · Post Graduate Institute of Medical Education and Research, Chandigarh (2) · Profil Institut für Stoffwechselforschung GmbH (2) · RWTH Aachen University (2) · Rabin Medical Center (2) · Amsterdam UMC, location VUmc (1)
United States (37) · Germany (36) · South Korea (22) · Canada (19) · China (18) · Mexico (18) · Spain (16) · Russia (15) · India (14) · Netherlands (13) · Philippines (12) · France (11) · Israel (11) · Italy (11) · Japan (11)
Rodolfo Guardado-Mendoza, MDPhD (3) · Nikolaus Marx, Univ.-Prof. (2) · Thomas Forst, MD, PhD (2) · Ahmed Elshafeey, Ph.D. Pharma (1) · Ahmed F El-Yazbi, PhD (1) · Ahmed I ElMallah, PhD (1) · Amr El-Feky, MD (1) · Angelo Avogaro, M.D. Ph.D. (1) · Anna Solini, MD, PhD (1) · Anton Cheng, MBBS (1) · Brian Kirkpatrick, MD (1) · Carlo B. Giorda, MD (1)
PMID 22234149, PMID 24169807, PMID 27484756, PMID 15882287, PMID 24279801, PMID 24344941, PMID 25236917, PMID 25307034, PMID 28533501, PMID 30862658, PMID 31539565, PMID 32328953, PMID 36116359, PMID 36700391, PMID 37449424, PMID 38170502, PMID 41665872, PMID 17098089, PMID 17622601, PMID 19732457, PMID 21781152, PMID 22748821, PMID 22816729, PMID 22939034, PMID 22974280, PMID 23134211, PMID 23521323, PMID 23524641, PMID 23645885, PMID 23672632, PMID 23948125, PMID 24062327, PMID 24824197, PMID 25583754, PMID 25629790, PMID 25633662, PMID 25780262, PMID 25805187, PMID 26224765, PMID 26695864, PMID 27281773, PMID 27583476, PMID 27586249, PMID 27684308, PMID 27733180, PMID 27762093, PMID 27913576, PMID 28109295, PMID 28183314, PMID 28290274
2008 (6), 2009 (6), 2016 (3), 2015 (2), 2017 (2), 2005 (1), 2014 (1), 2018 (1), 2025 (1)